In newly diagnosed NPM1-mutated AML patients treated with venetoclax combined with HMA or LDAC CR/CRi, rates up to 91% were observed, which were higher than the overall cohort (Table 3) [31,37,38,39,40,41,54]. Here, NPM1 is linked to acute myeloid leukemia.